Condition

Gastroesophageal-junction Cancer clinical trials and research

• 20Clinical trials
• 35Countries

Newest Gastroesophageal-junction Cancer clinical trials

All recruiting trials (20)

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Observational look at how adults with stomach and GEJ cancer are diagnosed and treated in Greece

  This study will look at real-world care for adults with stage II-IVB gastric or gastroesophageal junction cancer in Greece to see how they are diagnosed and managed in usual practice.

  Recruiting at 3 sites AstraZeneca · Alexandroupoli and 8 other locations · NCT07800754

• Comprehensive Prehabilitation Program for Locally Advanced Esophagogastric Cancer

  This trial tests if a personalized prehabilitation plan with nutrition, exercise, and psychological support helps patients with locally advanced esophageal, GEJ, or gastric cancer before surgery.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT07671625

• Cadonilimab with chemotherapy for gastric or GEJ cancer

  This trial tests whether adding cadonilimab to standard chemotherapy is safe and effective for adults with locally advanced or resectable gastric or GEJ cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07631000

• Proximal versus total gastrectomy for locally advanced Siewert type II–III gastroesophageal junction cancer

  This will see if keeping part of the stomach (proximal gastrectomy) or removing the whole stomach (total gastrectomy) leads to better 3-year disease-free survival for adults with locally advanced Siewert type II–III gastroesophageal junction cancer.

  Recruiting Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Istanbul, Istanbul · NCT07482566

• PF-08634404 plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma

  This trial will test whether adding the experimental medicine PF-08634404 to chemotherapy helps adults with newly diagnosed, locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma compared with nivolumab plus chemotherapy.

  Recruiting at 90 sites Phase 2/3 Pfizer · Atascadero, California and 101 other locations · NCT07392892

• QL1706 (Iparomlimab + Tuvonralimab) with SOX chemotherapy for untreated advanced or metastatic gastric or gastroesophageal junction cancer

  This trial will test whether adding QL1706 (two immunotherapy drugs) to SOX chemotherapy helps people with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer get a better tumor response.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07315854

• Adebrelimab with SHR-A1811/SHR-A1904 plus chemotherapy or with SHR-8068 for gastric and gastroesophageal-junction cancer

  This trial tests whether adding Adebrelimab to SHR-A1811 or SHR-A1904 plus chemotherapy, or combining Adebrelimab with SHR-8068, improves outcomes for adults newly diagnosed with gastric or gastroesophageal-junction cancer who have not yet received treatment.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shijiazhuang, Hebei and 1 other locations · NCT07110571

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

• Registry for esophageal and gastroesophageal junction cancer

  This study collects information from patients with newly diagnosed stage IV esophageal or gastroesophageal junction cancer to see how different treatments affect their quality of life and outcomes.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT06558786

• Treatment for HER2-positive gastric and gastroesophageal junction cancer

  This study is testing a new treatment combining HLX22, trastuzumab, and chemotherapy to see if it helps people with advanced HER2-positive stomach cancer feel better compared to standard treatment.

  Recruiting at 206 sites Phase 3 Shanghai Henlius Biotech · Anaheim, California and 207 other locations · NCT06532006

• Evaluating BL-M07D1 for HER2 Expressing Solid Tumors

  This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced solid tumors that have a specific protein called HER2 after they have tried other treatments.

  Recruiting at 24 sites Phase 1 SystImmune Inc. · Birmingham, Alabama and 25 other locations · NCT06293898

• Treatment with AZD0901 for advanced solid tumors expressing Claudin18.2

  This study is testing a new treatment called AZD0901 for people with advanced solid tumors that have a specific protein, to see if it works better alone or with other chemotherapy drugs.

  Recruiting at 44 sites Phase 2 AstraZeneca · Orange, California and 51 other locations · NCT06219941

• Combining radiotherapy and immunotherapy for limited metastatic gastric cancer

  This study is testing a new treatment that combines radiation, chemotherapy, and immunotherapy to see if it can help people with limited metastatic gastric cancer live longer and improve their health.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06121700

• IKS014 treatment for advanced solid tumors expressing HER2

  This study is testing a new treatment called IKS014 for people with advanced solid tumors that have HER2 to see how safe it is and if it can help shrink the tumors.

  Recruiting at 13 sites Phase 1 Iksuda Therapeutics Ltd. · Newport Beach, California and 12 other locations · NCT05872295

• Tislelizumab combined with chemoradiotherapy for advanced gastric cancer

  This study is testing if combining the immunotherapy drug Tislelizumab with chemoradiotherapy can help people with advanced stomach cancer do better before or after surgery compared to standard treatments.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Wuhan, Hubei and 2 other locations · NCT05687357

• Combination treatment for ctDNA positive gastric cancer

  This study is testing a new combination treatment for patients with a specific type of stomach cancer to see if it works better than the usual treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05494060

• CA-4948 combined with chemotherapy and immunotherapy for advanced gastric and esophageal cancer

  This study is testing a new treatment combining CA-4948 with chemotherapy and immunotherapy to see if it helps people with advanced stomach and esophageal cancer who haven't had other treatments yet.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT05187182

• Testing a new bispecific antibody for advanced solid tumors

  This study is testing a new treatment called MCLA-158 to see if it can help people with advanced solid tumors, especially those with metastatic colorectal cancer, when other options have run out.

  Recruiting at 45 sites Phase 1/2 Genmab · La Jolla, California and 53 other locations · NCT03526835

Related topics

Quick answers

How many Gastroesophageal-junction Cancer clinical trials are recruiting right now?

20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in United States (12 trials), China (9 trials), Spain (5 trials), Italy (4 trials), Japan (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 4, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →